Splenectomy Has No Role in the Standard Treatment of Advanced Peripheral T-Cell Lymphoma
Splenectomy is not recommended as part of the standard treatment algorithm for advanced peripheral T-cell lymphoma (PTCL). The established treatment approach for advanced PTCL focuses on systemic chemotherapy (CHOP or CHOEP regimens) followed by autologous stem cell transplantation in chemosensitive, transplant-eligible patients 1.
Evidence-Based Treatment Approach for Advanced PTCL
The ESMO Clinical Practice Guidelines clearly outline the treatment algorithm for advanced PTCL without any mention of splenectomy as a therapeutic intervention 1. The standard approach includes:
- First-line therapy: CHOP or CHOEP (for patients ≤60 years), with CHOEP-14 × 6 cycles followed by autoSCT showing 5-year OS of 47-70% depending on subtype 1
- Consolidation: Autologous stem cell transplantation for chemosensitive, transplant-eligible patients 1
- Relapse management: Clinical trial enrollment preferred; salvage chemotherapy (DHAP, ICE) followed by allogeneic SCT in eligible patients 1
Limited and Specific Exceptions
Splenectomy has only been described in highly specific, non-standard scenarios:
Hepatosplenic T-Cell Lymphoma (HSTCL)
This represents a unique exception where splenectomy may have a role, but only for managing severe thrombocytopenia that prevents administration of potentially effective chemotherapy 2. One case report demonstrated that splenectomy resolved grade 4 thrombocytopenia, allowing subsequent treatment with pralatrexate 2. However, HSTCL itself has dismal outcomes (5-year OS <10%) and requires intensive platinum/cytarabine-based regimens followed by transplantation 1.
T-Cell Large Granular Lymphocyte Leukemia
Splenectomy showed benefit for refractory cytopenia in T-LGL leukemia 3, but this is a distinct chronic lymphoproliferative disorder, not advanced PTCL.
Why Splenectomy Is Not Standard
The biological rationale for splenectomy in advanced PTCL is absent because:
- PTCL is a systemic disease: Advanced stage disease requires systemic therapy, not local interventions
- No survival benefit demonstrated: No evidence exists showing splenectomy improves mortality or quality of life in standard PTCL subtypes
- Guidelines do not support it: Neither ESMO 1 nor NCCN 4 guidelines include splenectomy in treatment algorithms for nodal PTCL subtypes (PTCL-NOS, AITL, ALCL)
Clinical Pitfalls to Avoid
- Do not delay systemic chemotherapy to pursue splenectomy in patients with splenomegaly and advanced PTCL
- Splenomegaly alone is not an indication for splenectomy in PTCL—it reflects disease burden requiring systemic treatment
- Diagnostic splenectomy may occasionally be needed when tissue diagnosis cannot be obtained elsewhere 5, but this is for diagnosis, not treatment
The Bottom Line
For advanced PTCL (PTCL-NOS, AITL, ALCL), proceed directly to systemic chemotherapy with CHOP/CHOEP followed by consolidative autoSCT in responding patients 1. Splenectomy should only be considered in the rare scenario of hepatosplenic T-cell lymphoma with severe refractory thrombocytopenia preventing chemotherapy administration 2, and even then, it serves as a bridge to systemic therapy rather than definitive treatment.